Clinical Trials Logo

Clinical Trial Summary

Objectives: Primary Objective The primary objective is to determine patients' perceptions of the timeliness of their referral to an outpatient palliative care clinic. The secondary objectives are to determine: 1. The factors and variables associated with perception of timeliness such as age, gender, and symptom distress 2. The patients' perceptions of the physical environment of the outpatient clinic at UT MD Anderson Cancer Center (UTMDACC) such as lighting, music, and lack of a waiting room; and 3. If there is an association between level of distress (physical, psychological, and spiritual distress as measured by Edmonton Symptom Assessment Scale (ESAS) and the usefulness of the referral to palliative care center.


Clinical Trial Description

If participant agrees to take part, they will complete 1 questionnaire over the phone, in person, or via e-mail about their first consultation experience, within 1 month after their visit. It should take about 15 minutes to complete. Health information about participant (such as their name, medical record number, telephone number, e-mail address, IP address, age, gender, race/ethnicity and cancer type) will also be collected but will not be shared with anyone outside of MD Anderson, except when required for regulatory purposes, or when required to be shared with study sponsors or study monitors. Participant's survey answers will not be shared with the Supportive Care staff. Distress Plan: Telephone - If participant experiences any distress while answering the survey questions, the research assistant will immediately contact our nurse in the Supportive Care Center. Participant will be contacted immediately to provide telephone counseling or address any other issue that may be causing distress. Our phone care nurse will offer participant to schedule a face-to-face visit with one of the Supportive Care physicians or to see a nurse in the Supportive Care Center. In-person - If participant experiences significant and high levels of distress while participating in the study, we will refer participant to their primary care physician, physician in the Supportive Care Center or one of the supportive care counselors. Online - If participant experiences significant and high levels of distress while completing the online survey, they may stop the survey and call the Supportive Care Center (during office hours) or the Supportive Care Mobile Team (after office hours or weekends). The contact information will be displayed on each page of the online survey. Patient's participation on the study will be over after they have completed the questionnaire. Participant's de-identified study information will be kept by the Principal Investigator in a locked file cabinet and password protected electronic study database for 5 years after publication of the research and then destroyed. Online survey responses, demographics, e-mail address, and IP address will be stored indefinitely in a secured database by the Qualtrics team. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02558257
Study type Observational
Source M.D. Anderson Cancer Center
Contact
Status Completed
Phase
Start date August 16, 2015
Completion date April 7, 2021

See also
  Status Clinical Trial Phase
Completed NCT01213238 - Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab Phase 1
Recruiting NCT02160366 - Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
Completed NCT00379353 - The Effects of Thalidomide on Symptom Clusters Phase 2
Completed NCT00903708 - LY2275796 in Advanced Cancer Phase 1
Terminated NCT00499382 - Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging N/A
Completed NCT02459964 - Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain Phase 4
Completed NCT01430572 - Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients Phase 1
Completed NCT02561234 - A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT01375114 - The Effects of Ginseng on Cancer-Related Fatigue Phase 2
Completed NCT01454804 - Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors Phase 1
Completed NCT01201694 - Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) Phase 1
Completed NCT02801045 - Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient N/A
Completed NCT02873975 - A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency Phase 2
Completed NCT01983969 - Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Phase 1/Phase 2
Completed NCT02272595 - Rational Therapeutics Based on Matched Tumor and Normal Tissue
Active, not recruiting NCT01999491 - A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma Phase 1
Recruiting NCT03375983 - Plasmodium Immunotherapy for Advanced Cancers Phase 1/Phase 2
Completed NCT02571036 - A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Phase 1
Withdrawn NCT01608139 - Study of Curcumin, Vorinostat, and Sorafenib Phase 1
Completed NCT01024166 - Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study N/A